← All trials
NCT04143607
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2019
- Primary completion
- Jan 31, 2021
- Completion date
- Aug 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 334
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.